Literature DB >> 9032990

Effect of glycosylation on antibody function: implications for genetic engineering.

A Wright1, S L Morrison.   

Abstract

Antibodies are able to both bind antigens and trigger the responses that eliminate them from circulation. All antibodies are glycosylated at conserved positions in their constant regions, and the presence of carbohydrate can be critical for antigen clearance functions such as complement activation. The structure of the attached carbohydrate can also affect antibody activity. Antibody glycosylation can be influenced by the cell in which it is produced, the conformation of the antibody and cell culture conditions. These variables should be considered in the design and production of antibodies with selected specificity and function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032990     DOI: 10.1016/S0167-7799(96)10062-7

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  57 in total

1.  Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.

Authors:  Lilit Aslanyan; Hiu H Lee; Vaibhav V Ekhar; Raddy L Ramos; Luis R Martinez
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Improving mass accuracy of high performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry of intact antibodies.

Authors:  Himanshu S Gadgil; Gary D Pipes; Thomas M Dillon; Michael J Treuheit; Pavel V Bondarenko
Journal:  J Am Soc Mass Spectrom       Date:  2006-04-21       Impact factor: 3.109

3.  Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.

Authors:  Ramil F Latypov; Sabine Hogan; Hollis Lau; Himanshu Gadgil; Dingjiang Liu
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

4.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 5.  N-glycoprotein macroheterogeneity: biological implications and proteomic characterization.

Authors:  Lucia F Zacchi; Benjamin L Schulz
Journal:  Glycoconj J       Date:  2015-12-05       Impact factor: 2.916

6.  Analysis of Monoclonal Antibody Sequence and Post-translational Modifications by Time-controlled Proteolysis and Tandem Mass Spectrometry.

Authors:  Lichao Zhang; A Michelle English; Dina L Bai; Scott A Ugrin; Jeffrey Shabanowitz; Mark M Ross; Donald F Hunt; Wei-Han Wang
Journal:  Mol Cell Proteomics       Date:  2015-11-29       Impact factor: 5.911

7.  Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.

Authors:  Carlos Vaccaro; Roger Bawdon; Sylvia Wanjie; Raimund J Ober; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

Review 8.  Ligand-targeted delivery of therapeutic siRNA.

Authors:  Yutaka Ikeda; Kazunari Taira
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

9.  Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.

Authors:  Hing-Yuen Yeung; Pui-Chi Lo; Dennis K P Ng; Wing-Ping Fong
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.